In any case, small molecule inhibitors are likely to have improved pharmacokinetics and our results lay the necessary groundwork to enable high-throughput screening for compounds that may disrupt the VPg-eIF4G interaction and so block infection. The gene discussed is EIF4G1; the disease is infection.